Researchers go after the Holy Grail in flu research with the first big study for a universal jab
Seventeen months after spinning out of Oxford, Vaccitech has lined up some big partners to help start the world’s first big human study of a universal flu vaccine.
The National Institute for Health Research is kicking this off by recruiting 500 patients over the age of 65, the most vulnerable group during every flu season.
Every year, seasonal flu vaccine manufacturers gear up to create vaccines that target the proteins that lie on the surface of flu cells, looking to kick up an immune response against it. But they’re slapping a puck that has to hit a moving target that’s still months away from declaring itself — a tough job that often misses its mark.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.